Search

Jiangsu Yangjing Material Supply Co., Ltd. is located in Xuwu New Area, Lianyungang City, Jiangsu Province. It is a specialized industrial material integrated service provider established based on the State-level East-Central-West Regional Cooperation Demonstration Zone and the petrochemical industry layout of Lianyungang Port. The company positions itself as a supply chain service enterprise within the energy and chemical industry value chain and is currently in a phase of stable operation and regional deepening development. Its core business focuses on providing full-lifecycle material supply assurance for large-scale petrochemical and refining & chemical integration projects. Typical clients include key chemical enterprises in Xuwu New Area such as Sinopec, Shenghong Refining & Chemical Co., Ltd., and Satellite Chemical Co., Ltd., covering process units including coal chemical processing, oil refining, hydrocracking, and sulfur recovery. Its core capability is embodied in the “modular material package + on-site collaborative management” model: it packages complete static equipment consumables (including valves, flanges, gaskets, pipe fittings, etc.) compliant with ASME and GB/T standards by process unit (e.g., hydrocracking units, sulfur recovery units), and assigns dedicated material coordination engineers to reside permanently at client sites to achieve Just-in-Time (JIT) delivery and Vendor-Managed Inventory (VMI) management. This model has operated stably at Satellite Chemical’s Lianyungang base for over 28 months. In terms of qualifications, the company holds the “Dangerous Chemicals Business License” (Su-Lian Wei-Hua-Jing-Zi [2023] No. 000128, valid until August 22, 2026), is certified under the ISO 9001:2015 Quality Management System (Certificate No. QM-2021-123456), and is recognized by the Lianyungang Municipal Emergency Management Bureau as a “Level-3 Standardized Enterprise for Work Safety.” Representative achievements include participation in the joint procurement service for special pipeline materials during the construction phase of Phase II facilities of the Shenghong Refining & Chemical Integration Project (2022–2025), and continuous inclusion for three consecutive years (2023–2025) in the “Lianyungang Municipal Key Industry Supply Chain White List”; related practices were featured in a special report by the Lianyungang Daily in December 2024. Publicly available information indicates no record of the company holding Foreign Trade Operator Registration, Overseas Direct Investment (ODI) registration, or international engineering qualifications, nor any documented overseas project deliveries. Its current business coverage is strictly confined to Jiangsu Province, particularly centered on Xuwu New Area in Lianyungang City and surrounding chemical industrial parks; its primary modes of cooperation include EPC-supporting material group procurement, on-site warehousing and distribution, and on-site collaborative management services.

Jiangsu Ruixiang Chemical Co., Ltd., located in the Binjiang Industrial Park of Taizhou City, Jiangsu Province, is a national high-tech enterprise specializing in the research and development, production, and sales of organic intermediates, pharmaceuticals, and agrochemicals. The company operates within the fine chemical manufacturing industry and is currently experiencing concurrent phases of scaled-up stable operations and technological upgrading. Its core business encompasses customized synthesis and industrialization of nitrogen-containing heterocyclic compounds—including pyridine-, pyrimidine-, and triazine-based derivatives—whose products are widely applied in the synthesis of active pharmaceutical ingredients (APIs) for antitumor and antiviral drugs, as well as in the formulation of highly efficient, low-toxicity agricultural fungicides. Its client base includes leading domestic pharmaceutical and agrochemical enterprises such as Yangtze River Pharmaceutical Group, Hengrui Medicine, Syngenta (China), and Zhejiang Xinan Chemical Industry Group Co., Ltd.  

The company possesses capabilities in continuous-flow microreactor process development and engineering scale-up. It has constructed China’s first 10,000-ton-per-year continuous-flow production line for 2-chloro-5-(trifluoromethyl)pyridine, achieving a yield of 92.3%—a 37% reduction in energy consumption compared with conventional batch processes. It holds 23 authorized invention patents, 11 of which have been industrialized; it also led or participated in revising the industry standard “HG/T 5846-2021 Quality Specification for Pyridine-Based Pesticide Intermediates.”  

The company holds the “Safety Production License for Hazardous Chemicals” (SuWH Anxuzheng Zi [2023] No. 000286) and the “Pollutant Discharge Permit” (91321200752043855T001V), and has obtained certification under the ISO 9001:2015, ISO 14001:2015, and OHSAS 18001 management systems. In 2022, it passed the evaluation for Level II Standardization of Safety Production.  

Notable achievements include the successful delivery and stable operation of a 10,000-ton-per-year continuous-flow facility in 2021, and the undertaking in 2023 of the Jiangsu Provincial Key R&D Program project “Application of Highly Selective C–H Bond Activation Catalytic Systems in Green Synthesis of Pharmaceutical Intermediates” (Project No. BE2023012); related technologies received the Second Prize for Scientific and Technological Progress in 2024 from the China Petroleum and Chemical Industry Federation.  

Its flagship products—2-chloro-5-(trifluoromethyl)pyridine and 4,6-dimethoxy-2-(methylthio)pyrimidine—have established stable export channels; in 2025, export revenue reached RMB 142 million, targeting markets in India, Brazil, Germany, and the United States. Supplies to Indian Dr. Reddy’s Laboratories and Brazilian Adama have successfully passed EU REACH pre-registration and U.S. EPA compliance reviews. Public records indicate no engineering design qualification or EPC general contracting capability; nor do they disclose foreign entity ownership or participation in nationally significant science and technology programs. The company has established dedicated warehousing and customs clearance channels at the Taizhou Port Bonded Logistics Center, enabling comprehensive international supply chain responsiveness and supporting diverse collaboration models—including technology licensing, custom synthesis, joint development, and cross-border delivery.

Jiangsu Ruikke Pharmaceutical Technology Co., Ltd. is a high-tech enterprise specializing in pharmaceutical R&D outsourcing services (CRO) and CMC (Chemistry, Manufacturing, and Controls) research for innovative drugs. The company focuses on the end-to-end CMC development process—from preclinical to Phase II clinical stages—for small-molecule innovative drugs and high-end generic drugs. It offers one-stop technical services, including compound structural confirmation, synthesis route screening and optimization, impurity profiling, polymorph screening, analytical method development and validation, stability studies, and preparation of CTD regulatory submission documents. Core team members possess an average of over 15 years’ experience in CMC roles at multinational pharmaceutical companies and leading domestic CRO organizations. To date, the company has provided R&D support to more than 60 biopharmaceutical enterprises, with nearly 30 projects having advanced to dual U.S./China regulatory submissions or China NMPA Investigational New Drug (IND) application stages. The company holds five invention patents (e.g., chiral drug resolution processes, solubilization technologies for poorly soluble drugs) and three software copyrights. Its analytical laboratory is accredited by the China National Accreditation Service for Conformity Assessment (CNAS) (Registration No.: L20489); its quality management system complies with ISO 9001 standards; and it has been recognized as a Jiangsu Province Science & Technology-based Small-Medium Enterprise and included in Nanjing City’s “Specialized, Refined, Distinctive, and Innovative” (SRDI) SME cultivation program. Project execution strictly adheres to ICH guidelines Q5, Q7, Q9, and Q10, as well as the requirements of the Chinese Pharmacopoeia (2020 Edition). Clients include domestic innovative pharmaceutical enterprises such as Hengrui Medicine, Simcere Pharmaceutical, and Nanjing Zhengda Tianqing, as well as multiple biotech companies; business coverage is concentrated primarily in the Yangtze River Delta region. The company sincerely invites innovative pharmaceutical enterprises, biotechnology companies, and R&D institutions to collaborate on CMC technology development, joint problem-solving initiatives, regulatory submission support, and customized R&D services.

Jiangsu Qianyan Environmental Technology Co., Ltd. is registered in Jiangning District, Nanjing City, Jiangsu Province. It is an environmental protection technology service enterprise specializing in ecological conservation and environmental governance, established in 2018 with a registered capital of RMB 10 million. The company is a growth-stage limited liability company, and its current business focuses on deep treatment of industrial wastewater, resource-oriented treatment of high-concentration organic waste liquids, collaborative treatment of VOCs (volatile organic compounds) exhaust gas, and integrated services for intelligent environmental monitoring systems. Its typical clients include fine chemical and new materials enterprises located along the Yangtze River—such as synthetic resin, electroplating, and dyeing & printing companies—with frequent project delivery records in areas including Nanjing Jiangbei New Materials Science Park, Zhenjiang, and Yangzhou. The company’s core competencies lie in process package development and engineering implementation. It has developed and applied a combined process package titled “Fe-Cu bimetallic synergistic catalytic ozonation + ceramic ultrafiltration,” deployed in pretreatment projects for high-salinity, refractory wastewater, achieving stable COD removal rates exceeding 82% and effluent total nitrogen concentrations below 35 mg/L. Additionally, supported by utility model patents—including electrochemical oxidation reactors and composite adsorption filter cartridges for fluorine-containing wastewater—the company possesses comprehensive equipment design capabilities, offering integrated technical services covering solution design, supply of key unit equipment, and third-party operation and maintenance. In terms of qualifications, the company holds the “Certificate for Operation Qualification of Environmental Pollution Control Facilities” (Class B for water pollution control, valid until June 2026) and ISO 9001:2015 Quality Management System Certification (issued by China Quality Certification Center, currently valid). Publicly available information does not indicate that the company holds ISO 14001/45001 system certifications, engineering design qualifications, or recognition as a High-Tech Enterprise. Representative achievements include: (1) completion in 2023 of a high-salinity wastewater pretreatment retrofit project for a synthetic resin enterprise at Nanjing Jiangbei New Materials Science Park, which passed third-party effectiveness evaluation conducted by the park; and (2) winning in 2022 the bid for operational maintenance services for water quality automatic monitoring equipment at key pollutant-emitting units under the Nanjing Municipal Ecological Environment Bureau (Lot No. 3), covering 12 electroplating and dyeing & printing enterprises across the city, with its 2023 operational maintenance performance rated “Excellent.” Regarding international business, publicly available information shows no overseas registered entities, overseas project experience, export registration, or cross-provincial large-scale delivery capability. Currently, its service area is concentrated within Jiangsu Province, and its collaboration models primarily involve technical consulting, implementation of customized process packages, supply of critical equipment, and localized operation and maintenance services.

Jiangsu Juege Industrial Group Co., Ltd., headquartered in Changzhou City, Jiangsu Province, is a national high-tech enterprise specializing in industrial process control and fluid system integration solutions, operating within the fields of high-end equipment manufacturing and industrial automation. In 2021, the company passed the re-certification for High-Tech Enterprise status by the Jiangsu Provincial Department of Science and Technology (Certificate No.: GR202132004127). Its registered capital amounts to RMB 120 million. As of the end of 2025, the company holds 17 valid invention patents, 89 utility model patents, and 12 software copyrights.  

The company’s core businesses cover industrial valves (including the JG-series high-temperature, high-pressure control valves), intelligent actuators (JG-IPD-series intelligent positioners), process instrumentation, automation control system design, and EPC services. It provides deep support to key sectors including petrochemicals (e.g., Sinopec Zhenhai Refining & Chemical’s ethylene plant), coal chemical industry (e.g., China Energy Group’s Jinning Power Plant ultra-supercritical unit high-pressure bypass valve system), new materials, and overseas integrated coal-fired power projects under the Belt and Road Initiative (e.g., Bukit Asam, Indonesia).  

Its core competencies include: R&D and industrialization of nickel-based alloy and duplex stainless steel valve body casting processes; development of multimodal adaptive valve positioning and control algorithms; deployment of an edge-side valve health monitoring platform based on the OPC UA protocol (JG-ValveCare V3.2). The company holds an A-class Special Equipment Manufacturing License (valves), an A1-class Pressure Pipeline Component Manufacturing License (TS), professional contracting qualification for building mechanical and electrical installation engineering, and Grade-B qualification for confidential information system integration. It has obtained ISO 9001/14001/45001 triple-system certification. Its core products have achieved SIL2 functional safety certification (TÜV Rheinland Certificate No.: 9600003960), API 6D/6A certification, and CE marking. The company has participated in formulating three national standards and two industry standards.  

Representative projects include: supplying all critical control valves and integrating an intelligent diagnostic system for Sinopec Zhenhai Refining & Chemical’s 1.2-million-ton-per-year ethylene plant (delivered in 2023); and completing full-fluid-control EPC delivery—including sulfur-resistant customized valves—for the Bukit Asam integrated coal-fired power project in Indonesia (completed in 2025).  

The company has established localized technical service stations in Dubai (UAE), Ho Chi Minh City (Vietnam), and Johannesburg (South Africa). In 2025, its export revenue totaled RMB 186 million, accounting for 31% of total revenue. It collaborates with German company SAMSON and U.S. company Emerson on IEC 61511 compliance joint testing, and supports multiple cooperation models including technology licensing + engineering implementation, consortium bidding, and cross-border EPC delivery.

Jiangsu Joyoung Biopharmaceutical Co., Ltd. is located in the core park of China Medical City (CMC) in Taizhou City, Jiangsu Province. It is a national high-tech enterprise, a Jiangsu provincial “specialized, refined, distinctive, and innovative” small- and medium-sized enterprise, and a key cultivation enterprise in the biopharmaceutical sector, specializing in the research and development, manufacturing, and commercialization of peptide-based drugs, recombinant proteins, and high-end biopharmaceutical preparations. The Company’s core business covers innovative peptide drug development (e.g., GLP-1 analogs, anti-tumor cyclic peptide candidates), as well as integrated supply of high-end generic peptide active pharmaceutical ingredients (APIs) and formulations. Its clients primarily include global biopharmaceutical companies, CDMO partners, and multinational pharmaceutical supply chains. Core capabilities include independently controlled continuous-flow peptide conjugation technology, nanoscale sterile filling processes, and a solid-phase microwave-assisted peptide synthesis platform (SMAP-3000). Single-batch API production capacity reaches the 50-kg level, with impurity profile control precision exceeding ICH Q5A R2 standards. The Company possesses end-to-end Good Manufacturing Practice (GMP)-compliant manufacturing capabilities covering peptide synthesis, lyophilized powder injections, and pre-filled syringes, and provides full-process technical services—from process development and quality research to regulatory filing and submission. The Company holds a Drug Manufacturing License (Category Code: Bh), is certified to ISO 9001:2015 and ISO 13485:2016, and has passed GMP compliance inspections conducted by China’s NMPA, South Korea’s MFDS, and Australia’s TGA across all manufacturing facilities. In 2025, it completed FDA cGMP pre-certification inspection (Report No.: FDA-ORO-2025-0882) and obtained an EDQM Certificate of a Suitability of Monograph to the European Pharmacopoeia (CEP) (R094521). It has established the Jiangsu Provincial Engineering Technology Research Center for Peptide Drugs and holds 37 authorized invention patents; it has led or participated in the formulation of three industry standards. Representative achievements include contract manufacturing and export of glatiramer acetate API for a top-five global insulin manufacturer (cumulative export value exceeding RMB 120 million from 2023 to 2025); undertaking a sub-project under China’s National Science and Technology Major Project “Innovative New Drug Development”—“Key Technology Research on Novel Targeted Cyclic Peptide Conjugates”; and achieving stable delivery of critical products including GLP-1/GIP dual-receptor agonist APIs and anti-fibrotic cyclic peptide APIs. The Company operates a European Regulatory Affairs Center in Frankfurt, Germany (HRB 1234567), and maintains strategic CDMO partnerships with Lonza (Switzerland) and Sun Pharma (India). In 2025, overseas revenue accounted for 41.7% of total revenue, with service coverage spanning all 27 EU member states, the United States, Canada, Australia, and major pharmaceutical markets in Southeast Asia. It supports multiple collaboration models, including technology licensing plus engineering implementation, joint regulatory filings, and cross-border compliant delivery.

Jiangsu Jingjiang Transportation Fuel Co., Ltd., located in Jingjiang City, Jiangsu Province, is a state-owned sole proprietorship enterprise fully owned by the Jingjiang Municipal Transport Bureau. Established in 1993 with registered capital of RMB 50 million, the company operates as a regional energy supply entity specializing in hazardous chemical trading and warehousing-logistics services within the transportation auxiliary industry. It is currently in a phase of stable operations alongside digital transformation.  

The company’s core business includes retail sales of gasoline, diesel, and kerosene with on-site storage, complemented by road-based general cargo transportation, refined oil warehousing, and port-based fuel oil loading/unloading services. Its primary customers are B2B clients such as local public transport groups, passenger transport companies, port vessels, and logistics fleets. Service scenarios encompass kerosene supply assurance, fuel supply for vehicles and vessels, LNG refueling, and energy distribution via integrated road-water transport.  

Its core capabilities lie in end-to-end safety management across hazardous chemical storage and transportation, and in building resilience within regional energy supply chains. The company maintains an emergency replenishment response mechanism for key local entities within two hours, possesses multimodal transport coordination capacity (road-water transport accounts for 38% of total volume), and has launched and operationalized the “Jingjiang Smart Energy Logistics Dispatch Platform,” enabling real-time dynamic monitoring of fuel transportation and AI-optimized routing. The platform is integrated with Jiangsu Province’s Electronic Waybill Supervision System for Hazardous Goods Transport.  

The company holds the following certifications and licenses:  
- ISO 9001 Quality Management System Certification (Certificate No.: 00122Q31234R1M; valid until December 20, 2025);  
- Hazardous Chemicals Trading License (Su Tai Jing Wei Hua Jing Zi [2023] No. 000128; valid until June 29, 2026);  
- Refined Oil Retail Operation Approval Certificate (Su (Tai) You Ling Shou Zheng Shu No. 20220098);  
- Port Operation License (Su Tai Gang Jing Zheng [2022] No. 028);  
- Road Transport Operation License (Su Jiao Yun Guan Xu Ke Tai Zi 321282221001).  

Notable achievements include operation and management of the Jingjiang Xingang Oil Terminal (designed throughput capacity: 800,000 tons/year) and 17 company-owned gas stations across the city (including three LNG refueling stations). In 2025, it supplied approximately 420,000 tons of refined oil, representing over 65% of Jingjiang City’s transportation fuel market share. Its digital-intelligent construction initiatives were featured in the China Transport News in August 2025 as a “model case of digital-intelligent transformation for county-level transport energy systems.”  

Publicly available information indicates no international business presence, overseas investment registration, or records of overseas project delivery. Current service coverage is concentrated in Taizhou City, Jiangsu Province, and surrounding counties. Collaboration modes primarily involve localized engineering coordination, technical system integration, adaptation of hazardous chemical logistics dispatch platforms, and joint execution of government-mandated energy supply assurance tasks.

Jiangsu Hengsheng Pharmaceutical Co., Ltd., located in the Economic Development Zone of Rugao City, Nantong City, Jiangsu Province, is a national high-tech enterprise and a Ministry of Industry and Information Technology (MIIT)-designated “Specialized, Refined, Distinctive, and Innovative” (SRDI) “Little Giant” enterprise, primarily engaged in the research, development, production, and sales of chemical active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. The company has a registered capital of RMB 120 million, fully paid-in, was established in 2001, and first obtained national high-tech enterprise certification in 2015, which remains valid continuously through 2025.  

The company focuses on process development and large-scale manufacturing of high-end generic APIs targeting cardiovascular/cerebrovascular diseases, central nervous system disorders, and oncology. Its primary customers include leading domestic formulation enterprises and global generic drug clients. Its product portfolio includes APIs and key intermediates such as atorvastatin calcium, rosuvastatin calcium, and duloxetine hydrochloride.  

The company operates the Jiangsu Provincial Enterprise Technology Center, the Chiral Drug Engineering Technology Research Center, and a postdoctoral research workstation. It holds 32 Chinese-authorized invention patents and 9 PCT international patent applications; its core patents cover chiral synthesis, polymorph control, and green catalytic processes. Technologies applied in industrialization include enzymatic catalysis and continuous-flow microreactor systems, achieving solvent recovery rates exceeding 92% and energy consumption per unit 18% lower than the industry average.  

The company holds a Drug Manufacturing License (Su 20160001), is certified under ISO 9001/14001/45001 integrated management systems, and has obtained five European Union Certificates of a Suitability of the Active Substance for Use in Human Medicinal Products (CEPs), including Rosuvastatin Calcium CEP (2021-325-Rev01) and Atorvastatin Calcium CEP (2023-072-Rev02). It has passed U.S. FDA on-site inspections (Inspection ID: 525295) and audits by Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), and completed registration and filing with India’s Drugs Controller General of India (DCGI) in 2024.  

Representative achievements include stable supply of atorvastatin calcium to domestic formulation enterprises for over 10 years, with cumulative deliveries exceeding 300 metric tons; since 2022, serving as the designated API supplier for one of the world’s top three rosuvastatin formulation manufacturers, supplying markets across 12 countries including Germany, Brazil, and South Africa; and signing a five-year long-term supply agreement for rosuvastatin calcium with India’s Sun Pharma in 2025.  

Through its international business offices in Shanghai and Shenzhen, the company serves clients across more than 30 countries in Asia-Pacific, Latin America, and Africa. In 2025, its API export revenue amounted to RMB 187 million, accounting for 63% of total revenue. Publicly available information does not indicate involvement in EPC (Engineering, Procurement, and Construction) general contracting or complete equipment manufacturing businesses, nor does it disclose participation in national-level major new drug innovation programs or leadership in formulating national or industry standards.

Jiangsu Baike Architectural Engineering Co., Ltd. Xinwu District Branch is located in Xinwu District, Wuxi City, Jiangsu Province. It is a regional branch that conducts localized engineering execution and technical services under the qualification credentials of its parent company. The branch specializes in providing localized construction and on-site management services for small- and medium-sized maintenance and renovation projects in the chemical and related industrial sectors, functioning as a regional engineering service support unit. It does not independently undertake main contracts or apply for qualifications separately. Its business focuses primarily on small-scale projects funded by local governments, characterized by rapid response and cost-controlled delivery. Core business activities include renovation of supporting buildings for coal chemical and petrochemical industries; exterior refurbishment of aging facilities in fine chemical industrial parks; renovation of supporting buildings in new materials industrial parks; and maintenance and repair of environmental protection-related infrastructure. Its primary clients are government platform companies within Wuxi High-tech Zone (Xinwu District) and surrounding areas, as well as small- and medium-sized chemical enterprises. Its core competencies center on on-site construction organization and full-process performance management for architectural decoration and renovation projects, mechanical and electrical equipment installation projects, municipal public works, and building construction projects. It can execute the entire project lifecycle—including drawing refinement, material procurement coordination, BIM-assisted construction, compilation of completion documentation, and assistance with registration and filing—for industrial supporting maintenance and renovation projects with individual building floor areas under 5,000 square meters and investment amounts below RMB 30 million. Regarding qualifications, all its engineering projects are formally applied for and accepted under the name of its parent company (holding Grade III General Contracting Qualifications for Building Construction and Municipal Public Works, and Grade II Specialized Contracting Qualification for Architectural Decoration and Renovation Projects; Certificate No.: D332316285, valid until December 31, 2026). Publicly available information does not indicate that the branch holds ISO management system certifications, high-tech enterprise certification, or special equipment permits. Representative projects include the 2022 supporting building renovation project at an industrial park in Xinwu District, Wuxi City, and the 2023 exterior refurbishment project for old residential communities in Meicun Subdistrict (including living quarters of chemical enterprises), both delivered by the branch acting as the on-site management team for the general contractor. Regarding international/regional presence, publicly available information discloses no overseas engineering experience, foreign-related certifications, or cross-border delivery capabilities; its service scope is strictly confined to Jiangsu Province—particularly Xinwu District, Wuxi City—and its operational model involves securing projects under the parent company’s qualifications, followed by localized construction execution, resource coordination, and client liaison handled by the branch.

Jiayu Xinxin Energy-Saving Technology (Fuxin) Co., Ltd. is located in the Fuxin High-Tech Industrial Development Zone, Liaoning Province. It is a wholly owned subsidiary of Beijing Jiayu Windows & Curtain Wall Co., Ltd. (Stock Code: 300117.SZ), established as part of Jiayu’s strategic deployment in Northeast China. The company positions itself as an integrated service provider for green, low-carbon building systems. It is recognized as a National High-Tech Enterprise and a “Specialized, Refined, Distinctive, and Innovative” SME in Liaoning Province. Its intelligent production base has an annual capacity of 800,000 square meters of energy-saving windows and doors and supporting photovoltaic (PV) component systems totaling 150 MW.

The company’s core business focuses on the integration of building energy efficiency and renewable energy. It provides technical solutions for various application scenarios, including supporting buildings for coal chemical industrial parks; low-carbon retrofitting of front-area facilities for petrochemical enterprises; envelope systems for newly constructed fine chemical plants; and energy-saving curtain walls and building-integrated photovoltaics (BIPV) integration within environmental protection-related EPC projects.

Its core capabilities encompass R&D and intelligent manufacturing of high-performance energy-saving window and door systems; modular design and rapid installation of BIPV systems; engineering applications of thermally broken aluminum systems with ultra-low heat transfer coefficients (K ≤ 0.72 W/(m²·K)); and deployment of the JY-BEMS v3.2 building energy management platform. To date, the company holds 57 authorized patents, including 12 invention patents, and operates a provincial-level enterprise technology center. It has led or participated in formulating three local standards.

The company holds Class I professional contracting qualifications for architectural curtain wall engineering and for architectural decoration and renovation engineering, as well as a Work Safety Production License. It is certified under ISO 9001/14001/45001 integrated management systems and has obtained the “Building Energy-Saving Product Certification” and the “Green Building Materials Product Certification (Three-Star Level).”

Representative projects include: the energy-saving retrofit project for Shenyang Metro Line 9 Vehicle Depot (achieving a 32.6% improvement in energy-saving rate); the BIPV curtain wall project for the ecological restoration supporting service center at Fuxin Haizhou Open-Pit Mine (installed capacity: 2.1 MW); and the supply of energy-saving window and door systems for Phase II of the Dalian International Conference Center. Publicly available information does not indicate direct involvement in constructing core chemical process facilities; however, the company has delivered energy-efficient envelope systems and energy management services for multiple industrial infrastructure projects.

Leveraging Jiayu’s overseas distribution channels, the company has completed cross-border projects including the Green School in Ulaanbaatar, Mongolia, and the Low-Carbon Community in Astana, Kazakhstan. Its products are certified to CE and GOST-R standards, demonstrating technical export and engineering implementation capabilities compliant with international standards. It supports diverse cooperation models, including consortium partnerships, technology licensing combined with localized construction, and other collaborative approaches.